[Efavirenz, Emtricitabine and Tenofovir (Simplir®) in HIV infection – comparison with other brands in Argentina]
González L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A.
Record ID 32018001392
Original Title: Efavirenz, emtricitabina y tenofovir (Simplir®) en infección por VIH: comparación con otras marcas comerciales disponibles en Argentina
Authors' recomendations: CONCLUSIONS Simplir® is one of the three brands under which the efavirenz, emtricitabine and tenofovir combination is commercially available in Argentina. The combination is considered an essential drug by the World Health Organization, being the standard of care in HIV infection. No evidence comparing the three commercially available brands in Argentina: Simplir® (Elea SACIF y A), Atripla® (Gador S.A,) and Trivenz® (Richmond SACIF) was found. A bioequivalence study between Simplir® and Atripla® is currently being carried out. According to Argentina’s National Administration of Medicaments, Food and Medical Technology (ANMAT) authorizations, the three brands contain the same drug, at the same dose and they are approved for the same indications.
Project Status: Completed
Year Published: 2017
URL for published report: https://www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
- HIV Infections
- Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
- Drug Therapy, Combination
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.